Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

IMPORTANCE: Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. OBJECTIVE: To assess whether patient outcomes in the LUX-Lung 8 trial were associated with ERBB gene family member aberrations in tumor specimens. DESIGN, SETTING, AND PARTICIPANTS: Ad...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Goss, Glenwood D., Felip, Enriqueta, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Li, Wei, Guclu, Salih, Isla, Dolores, Min, Young Joo, Morabito, Alessandro, Ardizzoni, Andrea, Gadgeel, Shirish M., Fülöp, Andrea, Bühnemann, Claudia, Gibson, Neil, Krämer, Nicole, Solca, Flavio, Cseh, Agnieszka, Ehrnrooth, Eva, Soria, Jean-Charles
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143014/
https://ncbi.nlm.nih.gov/pubmed/29902295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0775
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars